Endothelial cell growth factor (ECGF) is a potent polypeptide mitogen for endothelial cells and fibroblasts. The mitogenic effects of ECGF are inhibited by the lymphokine gamma-interferon (gamma-IFN) in a dose-dependent manner. Gamma-IFN also induces a unique change in endothelial cell morphology which is maximally expressed in the presence of ECGF. The antiproliferative and phenotypic modulatory effects of gamma-IFN on endothelial cells are reversible. Inhibition of ECGF-induced endothelial cell proliferation by gamma-IFN is accompanied by a concentration- and time-dependent decrease in binding of 125I-ECGF to the endothelial cell surface. Scatchard analyses of the binding data in the presence and absence of gamma-IFN demonstrate a decrease in the number of ECGF-binding sites rather than a decrease in ligand affinity for the receptor. Cross-linking experiments with disuccinimidyl suberate demonstrate a decrease in the 170,000 Mr cross-linked receptor-ligand complex. These data suggest that gamma-IFN inhibits endothelial cell proliferation by a mechanism which involves growth factor receptor modulation.
Article| March 01 1987
Inhibition of endothelial cell proliferation by gamma-interferon.
Online ISSN: 1540-8140
Print ISSN: 0021-9525
J Cell Biol (1987) 104 (3): 689–696.
R Friesel, A Komoriya, T Maciag; Inhibition of endothelial cell proliferation by gamma-interferon.. J Cell Biol 1 March 1987; 104 (3): 689–696. doi: https://doi.org/10.1083/jcb.104.3.689
Download citation file: